Evolent Health (EVH) Cash & Equivalents (2015 - 2026)

Evolent Health's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $142.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 42.4% year-over-year to $142.0 million; the TTM figure through Mar 2026 stood at $142.0 million (down 42.4% YoY), while the FY2025 annual figure was $151.9 million, up 45.73% from the prior year.
• Cash & Equivalents was $142.0 million for Q1 2026 at Evolent Health, down from $151.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $246.5 million in Q1 2025 to a low of $96.6 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $158.9 million across 5 years, with a median of $156.8 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 47.66% in 2024, then surged 49.29% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $188.2 million in 2022, then climbed by 2.46% to $192.8 million in 2023, then tumbled by 45.96% to $104.2 million in 2024, then surged by 45.73% to $151.9 million in 2025, then slipped by 6.49% to $142.0 million in 2026.
• The last three Cash & Equivalents figures came in at $142.0 million (Q1 2026), $151.9 million (Q4 2025), and $116.6 million (Q3 2025), per Business Quant data.